861 related articles for article (PubMed ID: 35797463)
1. Diagnosis and management of AML in adults: 2022 recommendations from an international expert panel on behalf of the ELN.
Döhner H; Wei AH; Appelbaum FR; Craddock C; DiNardo CD; Dombret H; Ebert BL; Fenaux P; Godley LA; Hasserjian RP; Larson RA; Levine RL; Miyazaki Y; Niederwieser D; Ossenkoppele G; Röllig C; Sierra J; Stein EM; Tallman MS; Tien HF; Wang J; Wierzbowska A; Löwenberg B
Blood; 2022 Sep; 140(12):1345-1377. PubMed ID: 35797463
[TBL] [Abstract][Full Text] [Related]
2. Diagnosis and management of AML in adults: 2017 ELN recommendations from an international expert panel.
Döhner H; Estey E; Grimwade D; Amadori S; Appelbaum FR; Büchner T; Dombret H; Ebert BL; Fenaux P; Larson RA; Levine RL; Lo-Coco F; Naoe T; Niederwieser D; Ossenkoppele GJ; Sanz M; Sierra J; Tallman MS; Tien HF; Wei AH; Löwenberg B; Bloomfield CD
Blood; 2017 Jan; 129(4):424-447. PubMed ID: 27895058
[TBL] [Abstract][Full Text] [Related]
3. Validation of the 2017 European LeukemiaNet classification for acute myeloid leukemia with NPM1 and FLT3-internal tandem duplication genotypes.
Boddu PC; Kadia TM; Garcia-Manero G; Cortes J; Alfayez M; Borthakur G; Konopleva M; Jabbour EJ; Daver NG; DiNardo CD; Naqvi K; Yilmaz M; Short NJ; Pierce S; Kantarjian HM; Ravandi F
Cancer; 2019 Apr; 125(7):1091-1100. PubMed ID: 30521114
[TBL] [Abstract][Full Text] [Related]
4. Validation of the prognostic significance of the 2022 European LeukemiaNet risk stratification system in intensive chemotherapy treated aged 18 to 65 years patients with de novo acute myeloid leukemia.
Lo MY; Tsai XC; Lin CC; Tien FM; Kuo YY; Lee WH; Peng YL; Liu MC; Tseng MH; Hsu CA; Chen JC; Lin LI; Sun HI; Chuang YK; Ko BS; Tang JL; Yao M; Chou WC; Hou HA; Tien HF
Am J Hematol; 2023 May; 98(5):760-769. PubMed ID: 36861732
[TBL] [Abstract][Full Text] [Related]
5. Real-world genomic profiling of acute myeloid leukemia and the impact of European LeukemiaNet risk stratification 2022 update.
da Rosa SEA; de Lima LB; Silveira CN; Cortes LGF; de Oliveira Filho JB; de Souza Reis R; Cervato MC; Rodrigues PHS; de Oliveira Pelegrino K; Petroni RC; da Silva Araujo E; Campregher PV
Clin Transl Oncol; 2023 Dec; 25(12):3431-3436. PubMed ID: 37165281
[TBL] [Abstract][Full Text] [Related]
6. IDH1 and IDH2 mutations are frequent genetic alterations in acute myeloid leukemia and confer adverse prognosis in cytogenetically normal acute myeloid leukemia with NPM1 mutation without FLT3 internal tandem duplication.
Paschka P; Schlenk RF; Gaidzik VI; Habdank M; Krönke J; Bullinger L; Späth D; Kayser S; Zucknick M; Götze K; Horst HA; Germing U; Döhner H; Döhner K
J Clin Oncol; 2010 Aug; 28(22):3636-43. PubMed ID: 20567020
[TBL] [Abstract][Full Text] [Related]
7. Acute Myeloid Leukemia: from Mutation Profiling to Treatment Decisions.
DiNardo C; Lachowiez C
Curr Hematol Malig Rep; 2019 Oct; 14(5):386-394. PubMed ID: 31350639
[TBL] [Abstract][Full Text] [Related]
8. Diagnosis and management of acute myeloid leukemia in adults: recommendations from an international expert panel, on behalf of the European LeukemiaNet.
Döhner H; Estey EH; Amadori S; Appelbaum FR; Büchner T; Burnett AK; Dombret H; Fenaux P; Grimwade D; Larson RA; Lo-Coco F; Naoe T; Niederwieser D; Ossenkoppele GJ; Sanz MA; Sierra J; Tallman MS; Löwenberg B; Bloomfield CD;
Blood; 2010 Jan; 115(3):453-74. PubMed ID: 19880497
[TBL] [Abstract][Full Text] [Related]
9. Prognostic analysis according to the 2017 ELN risk stratification by genetics in adult acute myeloid leukemia patients treated in the Japan Adult Leukemia Study Group (JALSG) AML201 study.
Harada Y; Nagata Y; Kihara R; Ishikawa Y; Asou N; Ohtake S; Miyawaki S; Sakura T; Ozawa Y; Usui N; Kanamori H; Ito Y; Imai K; Suehiro Y; Kobayashi S; Kitamura K; Sakaida E; Onizuka M; Takeshita A; Ishida F; Suzushima H; Ishizawa K; Naoe T; Matsumura I; Miyazaki Y; Ogawa S; Kiyoi H;
Leuk Res; 2018 Mar; 66():20-27. PubMed ID: 29360622
[TBL] [Abstract][Full Text] [Related]
10. 2021 Update on MRD in acute myeloid leukemia: a consensus document from the European LeukemiaNet MRD Working Party.
Heuser M; Freeman SD; Ossenkoppele GJ; Buccisano F; Hourigan CS; Ngai LL; Tettero JM; Bachas C; Baer C; Béné MC; Bücklein V; Czyz A; Denys B; Dillon R; Feuring-Buske M; Guzman ML; Haferlach T; Han L; Herzig JK; Jorgensen JL; Kern W; Konopleva MY; Lacombe F; Libura M; Majchrzak A; Maurillo L; Ofran Y; Philippe J; Plesa A; Preudhomme C; Ravandi F; Roumier C; Subklewe M; Thol F; van de Loosdrecht AA; van der Reijden BA; Venditti A; Wierzbowska A; Valk PJM; Wood BL; Walter RB; Thiede C; Döhner K; Roboz GJ; Cloos J
Blood; 2021 Dec; 138(26):2753-2767. PubMed ID: 34724563
[TBL] [Abstract][Full Text] [Related]
11. Diagnostic and therapeutic pitfalls in NPM1-mutated AML: notes from the field.
Falini B; Sciabolacci S; Falini L; Brunetti L; Martelli MP
Leukemia; 2021 Nov; 35(11):3113-3126. PubMed ID: 33879827
[TBL] [Abstract][Full Text] [Related]
12. Assessment of 2022 European LeukemiaNet risk classification system in real-world cohort from China.
Chen E; Jiao C; Yu J; Gong Y; Jin D; Ma X; Cui J; Wu Z; Zhou J; Wang H; Su B; Ge J
Cancer Med; 2023 Dec; 12(24):21615-21626. PubMed ID: 38098254
[TBL] [Abstract][Full Text] [Related]
13. How I diagnose and treat NPM1-mutated AML.
Falini B; Brunetti L; Martelli MP
Blood; 2021 Feb; 137(5):589-599. PubMed ID: 33171486
[TBL] [Abstract][Full Text] [Related]
14. Recent advances in management of acute myeloid leukemia (AML).
Shah M; Agarwal B
Indian J Pediatr; 2008 Aug; 75(8):831-7. PubMed ID: 18769895
[TBL] [Abstract][Full Text] [Related]
15. [AML in Adults - An Update on Diagnosis, Risk Classification and Therapy].
Spiekermann K; Shen AS
Dtsch Med Wochenschr; 2018 Sep; 143(18):1297-1303. PubMed ID: 30199909
[TBL] [Abstract][Full Text] [Related]
16. Applying molecular measurable residual disease testing in acute myeloid leukaemia.
Krigstein M; Iland HJ; Wei AH
Pathology; 2023 Feb; 55(1):1-7. PubMed ID: 36503638
[TBL] [Abstract][Full Text] [Related]
17. IDH1 and IDH2 mutations in patients with acute myeloid leukemia: Suitable targets for minimal residual disease monitoring?
Petrova L; Vrbacky F; Lanska M; Zavrelova A; Zak P; Hrochova K
Clin Biochem; 2018 Nov; 61():34-39. PubMed ID: 30176240
[TBL] [Abstract][Full Text] [Related]
18. Molecular alterations of isocitrate dehydrogenase 1 and 2 (IDH1 and IDH2) metabolic genes and additional genetic mutations in newly diagnosed acute myeloid leukemia patients.
Chotirat S; Thongnoppakhun W; Promsuwicha O; Boonthimat C; Auewarakul CU
J Hematol Oncol; 2012 Mar; 5():5. PubMed ID: 22397365
[TBL] [Abstract][Full Text] [Related]
19. Minimal Residual Disease in Acute Myeloid Leukemia.
Gomez-Arteaga A; Guzman ML
Adv Exp Med Biol; 2018; 1100():111-125. PubMed ID: 30411263
[TBL] [Abstract][Full Text] [Related]
20. How I treat AML incorporating the updated classifications and guidelines.
El Chaer F; Hourigan CS; Zeidan AM
Blood; 2023 Jun; 141(23):2813-2823. PubMed ID: 36758209
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
